|Bid||9.92 x 40700|
|Ask||9.98 x 27000|
|Day's Range||9.92 - 9.94|
|52 Week Range||3.49 - 10.30|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 01, 2023 - May 05, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Key Insights Apollo Endosurgery's estimated fair value is US$7.40 based on 2 Stage Free Cash Flow to Equity Apollo...
Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.